🔗 Share this article Patients Stopping Slimming Injections Gain Back Weight Far More Rapidly Than Those on Conventional Diets Weight management often requires long-term strategies. Fresh analysis suggests that people who come off popular slimming jabs like Mounjaro or Wegovy can put back on shed pounds far faster than those who end conventional lifestyle regimens. Findings released in a prominent health publication points out that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit. "Users using such drugs should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb. This pace of recovery implies a reversion to original weight in about one and a half years. Comparing Therapies The study, which examined dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting. The team point out that individuals who lose weight through dieting generally see a slower weight regain—around 100 grams monthly—after stopping. Understanding the Rapid Regain Nutrition scientists propose the mode of action of the drugs explains the accelerated weight return. GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger. "Artificially providing the hormone levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this medication leads to appetite is unsuppressed, making overeating far more likely." A Chronic Disease? Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications. Professionals contend that, given the high risk of relapse, the therapy is often life-long. This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," similar to managing diseases like diabetes. User Testimonies Users who have come off the jabs describe a powerful resurgence of hunger. "I experienced a trigger flipping and you're instantly extremely hungry," said one woman. This difficulty is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy. Widespread Use Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial. Adoption is more common among females than men. The 40s and 50s demographic shows the highest usage rates. Many access the drugs through private prescriptions rather than public health services. Ultimately, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and long-term success likely depends on combined lifestyle support.
Weight management often requires long-term strategies. Fresh analysis suggests that people who come off popular slimming jabs like Mounjaro or Wegovy can put back on shed pounds far faster than those who end conventional lifestyle regimens. Findings released in a prominent health publication points out that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit. "Users using such drugs should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb. This pace of recovery implies a reversion to original weight in about one and a half years. Comparing Therapies The study, which examined dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting. The team point out that individuals who lose weight through dieting generally see a slower weight regain—around 100 grams monthly—after stopping. Understanding the Rapid Regain Nutrition scientists propose the mode of action of the drugs explains the accelerated weight return. GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger. "Artificially providing the hormone levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this medication leads to appetite is unsuppressed, making overeating far more likely." A Chronic Disease? Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications. Professionals contend that, given the high risk of relapse, the therapy is often life-long. This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," similar to managing diseases like diabetes. User Testimonies Users who have come off the jabs describe a powerful resurgence of hunger. "I experienced a trigger flipping and you're instantly extremely hungry," said one woman. This difficulty is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy. Widespread Use Recent estimates suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial. Adoption is more common among females than men. The 40s and 50s demographic shows the highest usage rates. Many access the drugs through private prescriptions rather than public health services. Ultimately, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and long-term success likely depends on combined lifestyle support.